FIRST SUPPLEMENTAL INDENTUREFirst Supplemental Indenture • November 7th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of October 23, 2017, among Horizon Pharma Tepro, Inc., a Delaware corporation (the “Guaranteeing Entity”) an indirect subsidiary of Horizon Pharma, Inc., a Delaware corporation (the “Company”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”).
SECOND SUPPLEMENTAL INDENTURESecond Supplemental Indenture • November 7th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • New York
SECOND SUPPLEMENTAL INDENTURE (this “Second Supplemental Indenture”), dated as of May 10, 2016, between Horizon Pharma Rheumatology LLC (the “Guaranteeing Entity”), a parent or subsidiary of Horizon Pharma, Inc. (or its permitted successor), a Delaware corporation (the “Company”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”).
FIFTH SUPPLEMENTAL INDENTUREFifth Supplemental Indenture • November 7th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • New York
FIFTH SUPPLEMENTAL INDENTURE (this “Fifth Supplemental Indenture”), dated as of October 19, 2018, among Horizon Pharma Services LLC, a Delaware limited liability company (the “Guaranteeing Entity”) and an indirect subsidiary of Horizon Pharma, Inc., a Delaware corporation (the “Company”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”).
SIXTH SUPPLEMENTAL INDENTURESixth Supplemental Indenture • November 7th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • New York
SIXTH SUPPLEMENTAL INDENTURE (this “Sixth Supplemental Indenture”), dated as of October 31, 2018, between Horizon Pharma USA, Inc., a Delaware corporation (the “New Issuer”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”).
SECOND SUPPLEMENTAL INDENTURESecond Supplemental Indenture • November 7th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • New York
SECOND SUPPLEMENTAL INDENTURE (this “Second Supplemental Indenture”), dated as of October 19, 2018, among Horizon Pharma Services LLC, a Delaware limited liability company (the “Guaranteeing Entity”) and an indirect subsidiary of Horizon Pharma, Inc., a Delaware corporation (the “Company”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”).
THIRD SUPPLEMENTAL INDENTUREThird Supplemental Indenture • November 7th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • New York
THIRD SUPPLEMENTAL INDENTURE (this “Third Supplemental Indenture”), dated as of October 25, 2016, among Raptor Pharmaceutical Corp., a Delaware corporation, Raptor Pharmaceuticals Inc., a Delaware corporation (collectively, the “Guaranteeing Entities”), each a parent or subsidiary of Horizon Pharma, Inc. (or its permitted successor), a Delaware corporation (the “Company”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”).
FOURTH SUPPLEMENTAL INDENTUREFourth Supplemental Indenture • November 7th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • New York
FOURTH SUPPLEMENTAL INDENTURE (this “Fourth Supplemental Indenture”), dated as of October 23, 2017, among Horizon Pharma Tepro, Inc., a Delaware corporation (the “Guaranteeing Entity”) an indirect subsidiary of Horizon Pharma, Inc., a Delaware corporation (the “Company”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”).
CONFIDENTIAL SETTLEMENT AND LICENSE AGREEMENTSettlement Agreement • November 7th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • New Jersey
This Confidential Settlement And License Agreement (the “Settlement Agreement”) is entered into by and among HORIZON THERAPEUTICS, LLC, a corporation organized and existing under the laws of the State of Delaware with a principal place of business at 150 S. Saunders Road, Lake Forest, Illinois, 60045 (“Plaintiff”) and PAR PHARMACEUTICAL, INC. (“Par”), a corporation organized and existing under the laws of New York with a principal place of business at One Ram Ridge Road, Chestnut Ridge, NY 10977 (each individually a “Party”, collectively, the “Parties”), and made effective as of the date upon final execution of the Settlement Agreement by an authorized representative of each Party (the “Effective Date”).
AMENDMENT NO. 1 TO AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • November 7th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations
This Amendment No. 1 to the Amended and Restated License Agreement, (the “Amendment”) is entered into as of September 11, 2018 (the “Amendment Effective Date”), by and between:
